

StemBANCC (FP7-IMI-Seventh Framework Programme/Innovative Medicines Initiative)

<https://www.neurodegenerationresearch.eu/survey/stembancc-fp7-imi-seventh-framework-programmeinnovative-medicines-initiative/>

Infrastructure name

StemBANCC (FP7-IMI-Seventh Framework Programme/Innovative Medicines Initiative)

Institute/location

Key contact

Contact phone number

Contact email

Project/infrastructure description

Stem cells for Biological Assays of Novel drugs and predictive toxicology (StemBANCC)

Date funding committed

01/10/2012

Date infrastructure operational

Total capital cost (Euros)

€ 26,000,000

Does the 'Total Capital Cost' include other associated costs?

Current infrastructure status

Is this entry applicable to another section of this questionnaire?

Further information available at:

The aim of the STEMBANCC project is to generate and characterise 1 500 high quality human induced pluripotent stem (iPS) cell lines that can be used by researchers to study a range of diseases, including diabetes and dementia, and test for drug efficacy and safety. The cell lines will help to improve and speed up the drug development process, and ensure that patients benefit from more effective and safer drugs. Stem cells, iPSC, diabetes, neurological, toxicology, assay development, biobank

Types:

Capital Infrastructure

Member States:

European Commission

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A